Investing in AVITA Medical (RCEL) carries several risks inherent to commercial-stage biotechnology and medical device equities. Key vulnerabilities include ongoing net operating losses, reliance on the successful market adoption of its flagship RECELL technology, and potential delays in securing broader reimbursement approvals from public and private health insurers. Furthermore, the company faces execution risks associated with expanding its commercial sales force, navigating stringent regulatory oversight by agencies like the FDA, and managing cash burn rates before achieving sustained corporate profitability.